NeoCura    PV

TM

For virus prophylaxis, NeoCura develops prophylactic mRNA vaccines for different viruses. For selected viral antigen targets, NeoCura self-designed mRNA could express related antigens in vitro and in vivo with high efficiency, activating antigen specific humoral and cellular immune response, producing antibodies and memory cells, to achieve a safe and effective virus prophylactic goal.

MRNA vaccine induced immune response


Product Highlights




Self adjuvant effects

Non-cell cultured vaccine products, safer


Low toxicity and no integrating risk


Fast vaccine design



Technical Superiority

Self-developed sequence optimization plaform

Relatively simple and fast vaccine design

Simple and standardized manufacture.


Clinical Value

For sudden infection pandemic or virus infections with no vaccines currently available, mRNA vaccine could be designed with high speed and efficiency. 

mRNA vaccine is with relatively low toxicity, safe and reliable.

Scan code to follow us on WeChat

NeoCura Bio-Medical Technology Co., Ltd.

Beijing: Room C301, No. 29 Shengmingyuan Road, Life Science Park, Changping District, Beijing





Websitewww.neocura.com.cn

E-mailinfo@neocura.net

             bd@neocura.net

             pr@neocura.net

Tel+86 10 80766127




Guangzhou: 10/F, Block B, No. 388 Lianyun Road, Huangpu District, Guangzhou, China





Shenzhen: 12/F, Block B, Building 1, Yinxingzhijie Phase II, Longhua District, Shenzhen, China

Address:

  • Telephone

    • 010-80766127
  • ΢ɨһɨ

ض seo seo